JP2019508444A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508444A5 JP2019508444A5 JP2018548167A JP2018548167A JP2019508444A5 JP 2019508444 A5 JP2019508444 A5 JP 2019508444A5 JP 2018548167 A JP2018548167 A JP 2018548167A JP 2018548167 A JP2018548167 A JP 2018548167A JP 2019508444 A5 JP2019508444 A5 JP 2019508444A5
- Authority
- JP
- Japan
- Prior art keywords
- complex
- immune checkpoint
- peptide
- antigen
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 229940123309 Immune checkpoint modulator Drugs 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 229940122985 Peptide agonist Drugs 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 9
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 7
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 7
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 7
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 7
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 7
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 7
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 7
- 102000002689 Toll-like receptor Human genes 0.000 claims 7
- 108020000411 Toll-like receptor Proteins 0.000 claims 7
- 101150013553 CD40 gene Proteins 0.000 claims 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 6
- 239000012190 activator Substances 0.000 claims 6
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 5
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims 4
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 4
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 4
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 3
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 3
- 201000009813 cataract 31 multiple types Diseases 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 102100038078 CD276 antigen Human genes 0.000 claims 2
- 101710185679 CD276 antigen Proteins 0.000 claims 2
- 108010062802 CD66 antigens Proteins 0.000 claims 2
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims 2
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims 2
- 241000283070 Equus zebra Species 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 2
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims 2
- -1 ICOS Proteins 0.000 claims 2
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims 2
- 102000002698 KIR Receptors Human genes 0.000 claims 2
- 108010043610 KIR Receptors Proteins 0.000 claims 2
- 101150069255 KLRC1 gene Proteins 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 2
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 2
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 claims 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 claims 2
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 claims 2
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 claims 2
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims 2
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 claims 2
- 229940126546 immune checkpoint molecule Drugs 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/000472 WO2016146261A1 (en) | 2015-03-16 | 2016-03-16 | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
| EPPCT/EP2016/000472 | 2016-03-16 | ||
| EP2016070264 | 2016-08-26 | ||
| EPPCT/EP2016/070264 | 2016-08-26 | ||
| PCT/EP2017/056034 WO2017157964A1 (en) | 2016-03-16 | 2017-03-14 | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019508444A JP2019508444A (ja) | 2019-03-28 |
| JP2019508444A5 true JP2019508444A5 (2) | 2020-04-09 |
| JP7189021B2 JP7189021B2 (ja) | 2022-12-13 |
Family
ID=59851405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548167A Active JP7189021B2 (ja) | 2016-03-16 | 2017-03-14 | 医療において使用するための、免疫チェックポイントモジュレータと、細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む複合体との組合せ |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20190175748A1 (2) |
| EP (1) | EP3429618B1 (2) |
| JP (1) | JP7189021B2 (2) |
| AU (1) | AU2017234192B2 (2) |
| CA (1) | CA3010779A1 (2) |
| DK (1) | DK3429618T5 (2) |
| ES (1) | ES2977541T3 (2) |
| FI (1) | FI3429618T3 (2) |
| HR (1) | HRP20240510T1 (2) |
| HU (1) | HUE066998T2 (2) |
| LT (1) | LT3429618T (2) |
| PL (1) | PL3429618T3 (2) |
| PT (1) | PT3429618T (2) |
| RS (1) | RS65430B1 (2) |
| RU (2) | RU2769314C1 (2) |
| SI (1) | SI3429618T1 (2) |
| WO (1) | WO2017157964A1 (2) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2618842T3 (da) | 2010-09-22 | 2019-07-01 | Ena Therapeutics Pty Ltd | Hidtil ukendt immunstimulerende fremgangsmåde |
| US20180133327A1 (en) * | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| CA2984794A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods for using them |
| DK3429618T5 (da) | 2016-03-16 | 2024-09-16 | Amal Therapeutics Sa | Kombination af en immuncheckpoint-modulator og et kompleks som omfatter et cellepenetrerende peptid, en last og en tlr-peptidagonist til anvendelse i medicin |
| DK3515476T3 (da) | 2016-09-21 | 2024-09-02 | Amal Therapeutics Sa | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer |
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| WO2018187515A1 (en) | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| US11643463B2 (en) | 2017-05-19 | 2023-05-09 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| GB201810058D0 (en) * | 2018-06-19 | 2018-08-08 | Cytovation As | Combination therapy using a peptide |
| BR112021012536A2 (pt) | 2018-12-26 | 2021-09-14 | City Of Hope | Proteínas de ligação anti-ctla4 mascaradas ativáveis |
| WO2021042171A1 (en) * | 2019-09-04 | 2021-03-11 | Ena Therapeutics Pty Ltd | Cancer immunotherapy |
| EP4162037A1 (en) * | 2020-06-03 | 2023-04-12 | MV Biotherapeutics SA | Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof |
| US20220389065A1 (en) * | 2020-06-04 | 2022-12-08 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | Anticancer composition comprising tlr5 agonist derived from flagellin as active ingredient |
| EP4351639A4 (en) * | 2021-05-19 | 2025-05-21 | Queen's University At Kingston | COMBINATION TUMOR CELL VACCINE |
| CN113444687A (zh) * | 2021-05-31 | 2021-09-28 | 浙江圣希澳医学科技有限公司 | 穿膜肽介导肿瘤抗原多肽致敏转染cd40l的dc疫苗及dc-ctl方法 |
| WO2023076768A1 (en) * | 2021-10-26 | 2023-05-04 | Navicure Biopharmaceuticals Limited | Combination therapies against cancer and infectious diseases |
| CN113945723B (zh) * | 2021-10-28 | 2024-03-12 | 复旦大学附属中山医院 | 预测免疫检查点抑制剂治疗相关肺炎发生风险的系统、储存介质及其应用 |
| WO2023091747A1 (en) * | 2021-11-22 | 2023-05-25 | Axial Therapeutics, Inc. | Modulator compounds, pharmaceutical compositions and uses thereof |
| KR20240137685A (ko) | 2022-02-21 | 2024-09-20 | 유케어 파마슈티컬 그룹 컴퍼니 리미티드 | 바이러스 막 융합 억제제인 광범위 항-코로나바이러스 리포펩티드를 최적화하는 방법 및 그의 용도 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| FR2728904B1 (fr) | 1995-01-04 | 1997-03-14 | Pasteur Institut | Reactif peptidique permettant de detecter une infection primaire a virus d'epstein-barr par recherche des anticorps correspondants, et procede d'utilisation de ce reactif |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6750008B1 (en) | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| CZ303468B6 (cs) | 2000-02-23 | 2012-10-03 | Smithkline Beecham Biologicals S. A. | Imunogenní smes a farmaceutická smes |
| CA2427858A1 (en) | 2000-11-03 | 2002-05-10 | University Of Vermont And State Agricultural College | Compositions for inhibiting grb7 |
| US20060222656A1 (en) | 2005-04-01 | 2006-10-05 | University Of Maryland, Baltimore | MAGE-A3/HPV 16 peptide vaccines for head and neck cancer |
| AUPR593101A0 (en) | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| GB0218821D0 (en) | 2002-08-13 | 2002-09-18 | Glaxosmithkline Biolog Sa | Novel compositions |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| ATE552011T1 (de) | 2003-10-15 | 2012-04-15 | Ist Superiore Sanita | Kolorektal-karzinom-antigen |
| WO2006083301A2 (en) | 2004-06-17 | 2006-08-10 | Medimmune, Inc. | Immunogenic compositions comprising hmgb1 polypeptides |
| EP2287195B1 (en) | 2004-07-01 | 2019-05-15 | Novo Nordisk A/S | Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy |
| CN103143004A (zh) | 2005-02-04 | 2013-06-12 | 萨瓦克公司 | 存活蛋白肽疫苗 |
| ES2291071B1 (es) | 2005-06-13 | 2009-03-16 | Proyecto De Biomedicina Cima, S.L. | Agentes y metodos basados en el uso del dominio eda de la fibronectina. |
| CN103536915A (zh) | 2006-12-27 | 2014-01-29 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| BRPI0813621A2 (pt) | 2007-07-27 | 2017-05-09 | Immatics Biotechnologies Gmbh | imunoterapia contra tumores neuronais e cerebrais |
| RU2010107199A (ru) | 2007-07-31 | 2011-09-10 | Дзе Джонс Хопкинс Юниверсити (Us) | Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CN102046198A (zh) | 2008-04-25 | 2011-05-04 | 系统生物学研究所 | 鞭毛蛋白多肽疫苗 |
| SI2119726T2 (en) | 2008-05-14 | 2018-03-30 | Immatics Biotechnologies Gmbh | New and powerful Class II MHC peptides derived from survivin and neurocane |
| CA2728739C (en) | 2008-06-20 | 2017-07-11 | Duke University | Use of human cytomegalovirus antigens to enhance immune responses to cancer cells |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| KR101040281B1 (ko) | 2008-08-22 | 2011-06-10 | 가톨릭대학교 산학협력단 | Ｔａｔ-항원 융합단백질과 아쥬번트를 포함하는 백신 조성물 |
| US8074880B2 (en) | 2008-12-01 | 2011-12-13 | Research In Motion Limited | Method, system and mobile device employing enhanced fingerprint authentication |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| US9707285B2 (en) | 2009-03-16 | 2017-07-18 | Turnstone Limited Partnership | Vaccination methods |
| AU2010252012A1 (en) | 2009-05-27 | 2011-12-22 | Glaxosmithkline Biologicals S.A. | CASB7439 constructs |
| CN102762593B (zh) | 2009-07-31 | 2015-05-20 | 梅达雷克斯有限责任公司 | 抗btla的完全人抗体 |
| WO2011026122A2 (en) | 2009-08-31 | 2011-03-03 | Amplimmune, Inc. | B7-h4 fusion proteins and methods of use thereof |
| US20120237535A1 (en) | 2009-09-11 | 2012-09-20 | Proyecto De Biomedicina Cima, S.L. | Therapeutic Compositions For The Treatment of HPV-Induced Diseases |
| EP2480568B1 (en) | 2009-09-23 | 2016-04-20 | Université Paris Descartes | Polypeptides and nucleic acids for treating erbb2-dependent cancers |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011101332A1 (en) | 2010-02-16 | 2011-08-25 | Proyecto De Biomedicina Cima, S.L. | Compositions based on the fibronectin extracellular domain a for the treatment of melanoma |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2011135222A2 (fr) | 2010-04-26 | 2011-11-03 | Universite Joseph Fourier | Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles |
| WO2011140284A2 (en) | 2010-05-04 | 2011-11-10 | Fred Hutchinson Cancer Research Center | Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses |
| CA2801523C (en) | 2010-07-30 | 2021-08-03 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
| EP2608799B1 (en) | 2010-08-24 | 2018-12-12 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines |
| BR112013005970A2 (pt) | 2010-09-14 | 2016-07-05 | Council Scient Ind Res | imunógeno sintético, últil para gerar imunidade duradoura e proteção contra patógenos. |
| US9555074B2 (en) | 2010-10-08 | 2017-01-31 | Regents Of The University Of Minnesota | Annexin II compositions |
| KR101760464B1 (ko) | 2010-10-13 | 2017-07-24 | 사회복지법인 삼성생명공익재단 | 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도 |
| WO2012097012A1 (en) | 2011-01-10 | 2012-07-19 | Cleveland Biolabs, Inc. | Use of toll-like receptor agonist for treating cancer |
| US9187534B2 (en) | 2011-03-11 | 2015-11-17 | Universite De Geneve | Multi-epitopic vaccine |
| TWI454478B (zh) | 2011-05-13 | 2014-10-01 | Academia Sinica | 類鐸受體-２ 增效劑及其用於刺激免疫反應之用途 |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| JP6120848B2 (ja) | 2011-08-15 | 2017-04-26 | メディミューン，エルエルシー | 抗ｂ７−ｈ４抗体およびその使用 |
| WO2013067492A1 (en) | 2011-11-03 | 2013-05-10 | The Trustees Of The University Of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| HK1202252A1 (en) | 2011-11-16 | 2015-09-25 | Amgen Inc. | Methods of treating epidermal growth factor deletion mutant viii related disorders |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| WO2013120073A1 (en) * | 2012-02-09 | 2013-08-15 | Av Therapeutics, Inc. | Synthetic toll-like receptor-4 (tlr-4) agonist peptides |
| CN109806387B (zh) | 2012-07-13 | 2022-03-04 | S-目标疗法有限公司 | 免疫调节疫苗 |
| WO2014165101A1 (en) | 2013-03-13 | 2014-10-09 | California Stem Cell, Inc. | Individualized high purity colon carcinoma stem cells, methods and use of the same |
| RU2670488C2 (ru) * | 2012-09-13 | 2018-10-23 | Юниверсите Де Женев | Новые проникающие в клетку пептиды |
| CN104884065B (zh) | 2012-09-21 | 2019-01-01 | 强烈治疗剂公司 | 治疗癌症的方法 |
| WO2014070663A1 (en) | 2012-10-29 | 2014-05-08 | Anderson David E | Compositions and methods for diagnosis and treatment of malignant gliomas |
| AU2014346658A1 (en) | 2013-11-06 | 2016-06-02 | Solstice Biologics, Ltd. | Polynucleotide constructs having disulfide groups |
| ES2928331T3 (es) | 2013-11-13 | 2022-11-17 | Univ Minnesota | Composiciones de variantes de anexina II y métodos |
| PE20161344A1 (es) * | 2014-01-02 | 2016-12-23 | Memorial Sloan Kettering Cancer Center | Determinantes de respuesta del cancer a la inmunoterapia |
| JP2017522046A (ja) | 2014-06-06 | 2017-08-10 | ソルスティス バイオロジクス，リミティッド | 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物 |
| JP7523203B2 (ja) | 2014-10-31 | 2024-07-26 | マサチューセッツ インスティテュート オブ テクノロジー | 生体分子の免疫細胞への送達 |
| EP4098278A1 (en) | 2014-11-13 | 2022-12-07 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| BR102015025502B1 (pt) | 2015-04-30 | 2022-06-21 | Aegerion Pharmaceuticals, Inc | Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição |
| JPWO2017002345A1 (ja) | 2015-06-29 | 2018-04-19 | パナソニックＩｐマネジメント株式会社 | 冷蔵庫 |
| GB201520592D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| EP3778881A1 (en) | 2016-01-08 | 2021-02-17 | Replimune Limited | Modified oncolytic virus |
| WO2017120670A1 (en) | 2016-01-11 | 2017-07-20 | Brian Lichty | Oncolytic virus and checkpoint inhibitor combination therapy |
| DK3429618T5 (da) | 2016-03-16 | 2024-09-16 | Amal Therapeutics Sa | Kombination af en immuncheckpoint-modulator og et kompleks som omfatter et cellepenetrerende peptid, en last og en tlr-peptidagonist til anvendelse i medicin |
| CN109415705A (zh) | 2016-05-09 | 2019-03-01 | 图恩斯通有限合伙公司 | 组合初免:加强免疫疗法 |
| PL417980A1 (pl) | 2016-07-16 | 2018-01-29 | Univ Warszawski | Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu |
| WO2018053508A1 (en) | 2016-09-19 | 2018-03-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for inducing an immune response |
| DK3515476T3 (da) | 2016-09-21 | 2024-09-02 | Amal Therapeutics Sa | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer |
| US12303561B2 (en) | 2017-04-03 | 2025-05-20 | Biontech Us Inc. | Protein antigens and uses thereof |
| RU2020128830A (ru) | 2018-02-02 | 2022-03-03 | Новартис Аг | Комбинация агониста sting и il-15/il-15rа для лечения рака |
| CA3110102A1 (en) | 2018-06-20 | 2019-12-26 | Yale University | Rig-i agonists and treatments using same |
| WO2020010451A1 (en) | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| JP2023542297A (ja) | 2020-09-14 | 2023-10-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 異種プライムブーストワクチン |
| EP4228681A1 (en) | 2020-10-14 | 2023-08-23 | Boehringer Ingelheim International GmbH | Combination of a sting agonist and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist |
-
2017
- 2017-03-14 DK DK17711617.5T patent/DK3429618T5/da active
- 2017-03-14 WO PCT/EP2017/056034 patent/WO2017157964A1/en not_active Ceased
- 2017-03-14 PT PT177116175T patent/PT3429618T/pt unknown
- 2017-03-14 HR HRP20240510TT patent/HRP20240510T1/hr unknown
- 2017-03-14 PL PL17711617.5T patent/PL3429618T3/pl unknown
- 2017-03-14 CA CA3010779A patent/CA3010779A1/en active Pending
- 2017-03-14 HU HUE17711617A patent/HUE066998T2/hu unknown
- 2017-03-14 AU AU2017234192A patent/AU2017234192B2/en active Active
- 2017-03-14 FI FIEP17711617.5T patent/FI3429618T3/fi active
- 2017-03-14 RU RU2021109301A patent/RU2769314C1/ru active
- 2017-03-14 RU RU2018135097A patent/RU2748378C2/ru active
- 2017-03-14 US US16/084,170 patent/US20190175748A1/en not_active Abandoned
- 2017-03-14 SI SI201731513T patent/SI3429618T1/sl unknown
- 2017-03-14 RS RS20240451A patent/RS65430B1/sr unknown
- 2017-03-14 EP EP17711617.5A patent/EP3429618B1/en active Active
- 2017-03-14 JP JP2018548167A patent/JP7189021B2/ja active Active
- 2017-03-14 LT LTEPPCT/EP2017/056034T patent/LT3429618T/lt unknown
- 2017-03-14 ES ES17711617T patent/ES2977541T3/es active Active
-
2022
- 2022-01-05 US US17/569,261 patent/US12214048B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019508444A5 (2) | ||
| FI3429618T3 (fi) | Immuunijäjestelmän tarkistuspisteen modulaattorin ja soluun tunkeutuvan peptidin, cargon ja tlr-peptidiagonistin kompleksin yhdistelmä lääketieteelliseen käyttöön | |
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP2017529067A5 (2) | ||
| JP2018518939A5 (2) | ||
| JP2019507180A5 (2) | ||
| PE20190911A1 (es) | Composiciones y anticuerpos anti-lag-3 | |
| JP2020529841A5 (2) | ||
| JP2024023228A5 (2) | ||
| HRP20202024T1 (hr) | Cd3-vežuća domena | |
| JP2017537919A5 (2) | ||
| EP4296673A3 (en) | Peptides and methods for the detection of lyme disease antibodies | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2016536322A5 (2) | ||
| JP2018508219A5 (2) | ||
| IL258029B (en) | Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins | |
| JP2017508744A5 (2) | ||
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| RU2016124278A (ru) | Клетка | |
| NZ734803A (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
| JP2017502690A5 (2) | ||
| JP2019525771A5 (2) | ||
| RU2017142716A (ru) | Конструкции, направленные на комплексы пептида hpv16-e7/мнс, и виды их использования | |
| JP2018509936A5 (2) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение |